Publication:
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study

cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcidbed2f732-ad8f-46da-b23e-e9db6529c5f6
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcidd15fbd74-75d8-4d5c-af34-c5ddef96dc39
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid3ada9c2f-a4dd-4760-84b1-c48e64972bc5
cris.virtualsource.author-orcidf34c7371-748b-4478-8d2e-40dddd291954
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
dc.contributor.authorMueller, F
dc.contributor.authorBüchel, Barbara
dc.contributor.authorKöberle, D
dc.contributor.authorSchürch, Stefan
dc.contributor.authorPfister, B
dc.contributor.authorKrähenbühl, St
dc.contributor.authorFröhlich, Tanja
dc.contributor.authorLargiadèr, Carlo Rodolfo
dc.contributor.authorJoerger, M
dc.date.accessioned2024-10-11T13:37:27Z
dc.date.available2024-10-11T13:37:27Z
dc.date.issued2013
dc.description.abstractThis study was initiated to assess the quantitative impact of patient anthropometrics and dihydropyrimidine dehydrogenase (DPYD) mutations on the pharmacokinetics (PK) of 5-fluorouracil (5FU) and to explore limited sampling strategies of 5FU.
dc.description.numberOfPages10
dc.description.sponsorshipUniversitätsinstitut für Klinische Chemie (UKC)
dc.description.sponsorshipDepartement für Chemie und Biochemie (DCB)
dc.identifier.doi10.48350/14661
dc.identifier.isi000314044200010
dc.identifier.pmid23139054
dc.identifier.publisherDOI10.1007/s00280-012-2018-4
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/84720
dc.language.isoen
dc.publisherSpringer
dc.publisher.placeBerlin
dc.relation.ispartofCancer chemotherapy and pharmacology
dc.relation.issn0344-5704
dc.relation.organizationDCD5A442BA49E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442C14DE17DE0405C82790C4DE2
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc500 - Science::570 - Life sciences; biology
dc.subject.ddc500 - Science::540 - Chemistry
dc.titleGender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage70
oaire.citation.issue2
oaire.citation.startPage361
oaire.citation.volume71
oairecerif.author.affiliation#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliationUniversitätsinstitut für Klinische Chemie (UKC)
oairecerif.author.affiliation#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliationDepartement für Chemie und Biochemie (DCB)
oairecerif.author.affiliation#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliationUniversitätsinstitut für Klinische Chemie (UKC)
oairecerif.author.affiliationUniversitätsinstitut für Klinische Chemie (UKC)
oairecerif.author.affiliation#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation2#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation2#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation2#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation2#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation2#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation2#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation2#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation2#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation2#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation3#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation3#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation3#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation3#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation3#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation3#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation3#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation3#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation3#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation4#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation4#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation4#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation4#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation4#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation4#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation4#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation4#PLACEHOLDER_PARENT_METADATA_VALUE#
oairecerif.author.affiliation4#PLACEHOLDER_PARENT_METADATA_VALUE#
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2022-07-07 12:57:59
unibe.description.ispublishedpub
unibe.eprints.legacyId14661
unibe.journal.abbrevTitleCANCER CHEMOTH PHARM
unibe.refereedTRUE
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Mueller2013_Article_Gender-specificEliminationOfCo.pdf
Size:
380.8 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
published

Collections